FDA approves a second Alzheimer’s drug that can modestly slow disease

The FDA has approved a second drug for the treatment of Alzheimer’s disease that can modestly slow the progression of the disease. This new drug, called Aduhelm, has shown promising results in clinical trials and offers hope for patients and their families. While not a cure, the approval of this drug marks a significant step forward in the fight against Alzheimer’s.

Source link